The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022

Saranya Sridhar (), Roman M. Chicz, William Warren, Jim Tartaglia, Stephen Savarino, Sanjay Gurunathan and Jean-Francois Toussaint
Additional contact information
Saranya Sridhar: Sanofi
Roman M. Chicz: Sanofi
William Warren: Sanofi
Jim Tartaglia: Sanofi
Stephen Savarino: Sanofi
Sanjay Gurunathan: Sanofi
Jean-Francois Toussaint: Sanofi

Nature Communications, 2022, vol. 13, issue 1, 1-3

Abstract: Currently approved COVID vaccines are designed using the spike antigen derived from the ancestral strain, but health authorities are recommending changes to the vaccine strain to combat emerging variants. The goal is to ensure that next generation vaccines can tackle multiple variants of concern including the most prevalent variant for the coming season. We here discuss recent preclinical and clinical data on COVID vaccine antigens that are potential candidates for an updated vaccine.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33549-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33549-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33549-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().